Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: An analysis of 657 patients

American Journal of Surgical Pathology

Volumn 33, Issue 12, 2009, Pages 1802-1808

  Collins, Laura C ^a   Achacoso, Ninah ^b   Nekhlyudov, Larissa ^a,c   Fletcher, Suzanne W ^a   Haque, Reina ^d   Quesenberry, Charles P ^b   Puligandla, Balaram ^d   Alshak, Najeeb S ^e   Goldstein, Lynn C ^f   Gown, Allen M ^f   Schnitt, Stuart J ^a   Habel, Laurel A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DIVISION OF RESEARCH   (United States)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^d KAISER PERMANENTE   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f PHENOPATH LABORATORIES   (United States)

Author keywords

Breast cancer; Ductal carcinoma in situ; Young age

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BIOPSY; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RADIOGRAPHY; REGISTER; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGE FACTORS; AGED; BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 73349116209     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181b7cb7a     Document Type: Article

References (31)

1. Baer HJ, Collins LC, Connolly JL, et al. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer. 2009;115:1404-1411.
2. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19:2263-2271.
3. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381-3387.
4. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-7360.
5. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644.
6. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys. 2002;53:868-879.
7. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-1586.
8. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353:1993-2000. (Pubitemid 29271743)
9. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28:400-418. (Pubitemid 32762083)
10. Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol. 2000;24:1058-1067. (Pubitemid 30612827)
11. Goldstein NS, Vicini FA, Kestin LL, et al. Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. Cancer. 2000;88:2553-2560.
12. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271-1277.
13. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95-102.
14. Imamura H, Haga S, Shimizu T, et al. Relationship between the morphological and biological characteristics of intraductal components accompanying invasive ductal breast carcinoma and patient age. Breast Cancer Res Treat. 2000;62:177-184.
15. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692-1702.
16. Meijnen P, Oldenburg HS, Peterse JL, et al. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol. 2008;15:235-243.
17. Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst. 2006;98: 1600-1607.
18. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
19. Ohtake T, Abe R, Kimijima I, et al. Intraductal extension of primary invasive breast carcinoma treated by breast-conservative surgery. Computer graphic three-dimensional reconstruction of the mammary duct-lobular systems. Cancer. 1995;76:32-45.
20. Rodrigues NA, Dillon D, Carter D, et al. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer. 2003;97: 1393-1403. (Pubitemid 36297768)
21. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14: 8010-8018.
22. Solin LJ, McCormick B, Recht A, et al. Mammographically Detected, Clinically Occult Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Definitive Breast Irradiation. Cancer J Sci Am. 1996;2:158.
23. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103: 1137-1146. (Pubitemid 40328083)
24. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10:R67.
25. Tavassoli FA, Hoefler H, Rosai J, et al. Intraductal Proliferative Lesions. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics: Tumor of the Breast and Female Genital Organs. Lyons: IARC Press; 2003:63-73.
26. Turaka A, Freedman GM, Li T, et al. Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol. 2009.
27. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19:97-105.
28. Van Zee KJ, Liberman L, Samli B, et al. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86:1757-1767.
29. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys. 2005;63: 1514-1521.
30. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18:296-306.
31. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3-11.